Delivery Order SPE2DB22D3301-SPE2DB26FX3QX
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $29,860.78 for Dupixent 300 mg/2 ml syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which is not set-aside, will be performed at the company's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions, making...
- The Defense Logistics Agency awarded a $69,305.82 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on May 27, 2025, with completion scheduled for May 28, 2025. This firm fixed price contract represents a non-competitive set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly prescribed for severe asthma, eczema, and other inflammatory conditions, making this delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,522.23 for Dupixent (dupilumab) 300 mg/2 mL syringes on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $79,236.52 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL syringes on September 4, 2025, with completion targeted for September 5, 2025. This competitive, firm fixed-price award carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions, including asthma, atopic...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for Dupixent 200mg/1.14ml syringes totaling $11,966.22 under a firm fixed price contract. This competitively awarded, non-set-aside delivery order is scheduled for completion by August 15, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat...
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $13,785.71 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml syringes on September 18, 2025, with an ultimate completion date of September 19, 2025. This firm fixed price, non-set-aside contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly prescribed for conditions including moderate-to-severe atopic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml syringes on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $8,010.37 to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Dupixent 300 mg/2 ml syringes with an ultimate completion date of September 17, 2025. This competitively awarded, firm fixed price delivery order carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory...
- The Defense Logistics Agency awarded a $18,005.78 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3QXDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,756.97 for Dupixent 300 mg/2 mL syringes on October 21, 2025, with an ultimate completion date of October 22, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including asthma, eczema, and chronic obstructive pulmonary disease, reflecting the Defense Logistics Agency's ongoing pharmaceutical supply requirements for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement extending through December 2026. As a leading pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications, vaccines, and medical devices to support global military healthcare programs through this master contract vehicle, which enables flexible procurement of pharmaceutical products across multiple therapeutic domains for the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.8k | 10/21/25 |